- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00721240
Investigation to Identify Predictors of Response to a Treatment With Montelukast
Study Overview
Detailed Description
Leukotriene antagonists (montelukast) are particularly effective as controllers before exposure to an allergen (Leff 1998). The same applies to the treatment of bronchoconstriction induced by physical exertion or cold air (Richter 2000). Montelukast binds to the cysteinyl leuko¬triene-1 receptor, where it prevents leukotriene from binding. Leukotrienes play a key role as mediators in inflammatory processes. By binding to the receptor they cause, among other things, edema, damage to the bronchial epithelium and bronchoconstriction. Accordingly, in addition to its anti-inflammatory activity montelukast brings about bronchial dilation. The safety and efficacy of the drug in children have been well documented (Knorr 1998). Hence montelukast is approved for the treatment of bronchial asthma in children (over six months of age). As with other antiasthmatic drugs, there are responders and nonresponders to leukotriene receptor antagonists. The proportion of nonresponders to montelukast among children is esti¬mated to be 30% to 40%. At present the only way to distinguish non-responders from responders is to run a treatment trial for several weeks. If the symptom score falls, if the use of beta2 sympathomimetics is reduced, if pulmonary function and/or the quality of life improves, it is assumed that the patient is a responder. This method is not only tedious but also unsafe, since a change is the aforementioned parameters could occur spontaneously, without this being reliably attributable to the influence of the drug. In the planned study approximately 30 children with asthma of GINA classes 2 and 3 will be regularly examined for pulmonary function, symptom score and nitrogen monoxide (NO). First, however, the acute pharmacologic effect of a single dose of montelukast will be deter¬mined over a period of four hours by measuring pulmonary function and levels of exhaled nitrogen monoxide (NO).
4.2.1. Questions addressed:
Is it possible to discriminate between responders and nonresponders at a very early stage on the basis of the acute pharmacologic effect of montelukast? Does this classification agree with the results after 12 weeks of treatment?
4.2.2. Hypothesis:
Patients who show a bronchospasmolytic effect in their functional pulmonary test (FEV1 increased by at least 5%) within four hours of taking montelukast also show a positive response (defined as a combination of at least two variables (see section on the definition of responders/non-responders during treatment)) after 12 weeks of treatment. Conversely, patients who show no acute effect do not have a positive response during long-term therapy.
In other words, the results of the acute pharmacologic effect correspond to the effect during long-term therapy.
5. Aim of the study:
The main aim of the study is to develop a method that allows responders to be distinguished from non-responders before long-term treatment is initiated. Subsidiary aims are to record changes in pulmonary functional parameters, NO concentrations and peak flow variability, the use of beta2 sympathomimetics and the asthma symptom score.
6. Patient selection:
The study will include approximately 30 patients aged 6 to 14 years with diagnosed bronchial asthma who have been on constant anti-inflammatory therapy for at least four weeks (GINA classes 2 and 3).
7. Study design:
This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
NRW
-
Wesel, NRW, Germany, 46483
- Marien Hospital Wesel gGmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children and adolescents with symptomatic bronchial asthma despite ongoing therapy
- Age 6-14 years
- Asthma diagnosed at lease six months previously (by a special pulmonary allergologic outpatient unit)
- Demonstration of reversibility (FEV1 increased by at least 12% after bronchospasmolysis with a beta2 sympathomimetic). This can be determined at the screening visit or within the previous three months.
Patients who are either steroid-naive or who received constant doses of the following medi¬cations within the previous four weeks:
- Beclomethasone dipropionate: up to 400 µg daily
- Fluticasone propionate: up to 200 µg daily
- Budesonide: up to 400 µg daily
- Patients who are able to reliably complete the asthma diary and perform peak flow measurements according to instructions.
- Girls of childbearing potential must have acceptable methods of contraceptions, including sexual abstinence.
Exclusion Criteria:
- Patients who were treated with systemic steroids within the previous 30 days
Patients using one of the following asthma medications:
- Systemic steroids
- Nedocromil, DNCG
- Theophylline
- Ketotifen
- Systemic or long-acting beta2 sympathomimetics
Patients who have experienced one of the following events within the previous 30 days:
- A change in asthma medication
- Pulmonary infection
- Hospitalization due to bronchial asthma or any other respiratory condition
- Patients who are currently participating in another clinical trial or have done so within the previous 30 days.
- Patients known or expected to react hypersensitively to components of the investigational medication
- Patients receiving Phenobarbital, Phenytoin, Rifampicin (medications that are metabolized by Cytochrom P450
- Patients with analgetic intolerance
- Pregnant females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single-arm
This investigation is a single-center, two-phase, single-arm study.
In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
|
5mg montelukast once daily for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patients who show a bronchospasmolytic effect in their functional pulmonary test (FEV1 increased by at least 5%) within four hours of taking montelukast.
Time Frame: 14 days after run in
|
14 days after run in
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
symptom score, PEAK-Flow, rescue medication, exhaled NO
Time Frame: 2 weeks after run in and 14 weeks after run in
|
2 weeks after run in and 14 weeks after run in
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: ANDREA VON BERG, MD, Marien Hospital Wesel; FORSCHUNGSINSTITUT ZUR PRÄVENTION VON ALLERGIEN UND ATEMWEGSERKRANKUNGEN IM KINDESALTER AN DER kLINIK FÜR KINDER UND JUGENDMEDIZIN
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- Trial No. 25.08.2005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on montelukast
-
Indiana UniversityCompleted
-
Chinese University of Hong KongUniversity of Sydney; Chongqing Medical University; Hong Kong University of Science... and other collaboratorsNot yet recruitingAtherosclerosis, CoronaryHong Kong
-
GlaxoSmithKlineCompleted
-
Kecioren Education and Training HospitalCompletedAsthma | Acute AsthmaTurkey
-
Menarini International Operations Luxembourg SACompletedAsthma | Seasonal Allergic RhinoconjunctivitisPoland, Romania, Germany, Italy, Czechia, Latvia, Croatia, Slovakia
-
Organon and CoCompleted
-
GlaxoSmithKlineCompletedRespiratory Disorders | Asthma and RhinitisIndia
-
Medical University of LodzUnknownSeasonal Allergic RhinitisPoland
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Kecioren Education and Training HospitalCompletedAcute Asthma | Acute Wheezy BronchitisTurkey